GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » Total Long-Term Assets

Virax Biolabs Group (Virax Biolabs Group) Total Long-Term Assets : $1.05 Mil (As of Sep. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Virax Biolabs Group Total Long-Term Assets?

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Virax Biolabs Group's Total Long-Term Assets for the quarter that ended in Sep. 2023 was $1.05 Mil.


Virax Biolabs Group Total Long-Term Assets Historical Data

The historical data trend for Virax Biolabs Group's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virax Biolabs Group Total Long-Term Assets Chart

Virax Biolabs Group Annual Data
Trend Mar20 Mar21 Mar22 Mar23
Total Long-Term Assets
- - - 0.18

Virax Biolabs Group Semi-Annual Data
Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Total Long-Term Assets Get a 7-Day Free Trial - - - 0.18 1.05

Virax Biolabs Group Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.


Virax Biolabs Group Total Long-Term Assets Related Terms

Thank you for viewing the detailed overview of Virax Biolabs Group's Total Long-Term Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Virax Biolabs Group (Virax Biolabs Group) Business Description

Traded in Other Exchanges
N/A
Address
20 North Audley Street, London, GBR, W1K 6LX
Virax Biolabs Group Ltd is a innovative biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.